Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and ...

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research ...

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research ...

H.C. Wainwright lowered the firm’s price target on Assertio Holdings (ASRT) to $3.50 from $4 and keeps a Buy rating on the shares following the ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

Fintel reports that on March 17, 2025, HC Wainwright & Co. downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

H.C. Wainwright initiated coverage of Alpha Cognition (ACOG) with a Buy rating and $20 price target Alpha is an emerging specialty ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...

Financial giants have made a conspicuous bearish move on SpringWorks Therapeutics. Our analysis of options history for ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.

Whatever is good for CoreWeave is probably good for Core Scientific, but the IPO might not be the most important recent ...